The Role hMSCs Play in Bioengineering Solutions for Military Medicine

Published on : Published by : Chris Frew

Join us on Tuesday, June 14th at 11:00 AM EST for RoosterBio’s client-led seminar: The Role hMSCs Play in Bioengineering Solutions for Military Medicine. We will be joined by Lorena [….]

TELA Bio Secures Up to $50M in Debt Financing from MidCap Financial 

Published on : Published by : BioBuzz Media

TELA Bio Secures Up to $50M in Debt Financing from MidCap Financial
Nereida S. Franks May 31, 2022 Debt financing
MALVERN, Pa., May 31, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative tissue reconstruction solutions soft tissues that optimize clinical outcomes by prioritizing the preservation and restoration of patient anatomy, today announced that the company has entered into a new credit facility with MidCap Financial (“MidCap”), enabling TELA to access a total credit of up to $50 million. A portion of the proceeds from the new credit facility was used to fully repay TELA’s existing $30 million credit facility with OrbiMed Royalty Opportunities II, LP, with the remaining proceeds from the credit facility available for servicing. working capital and for other corporate purposes.
“We are excited about our new partnership with MidCap which provides TELA with cost effective financing and financial flexibility. This transaction reflects TELA’s strong financial position and outlook, which has allowed us to access the debt capital markets for non-dilutive financing,” said Antony Koblish, President and CEO of TELA Bio. “The proceeds of this loan will allow TELA to fund its current key business objectives and…

Gene Editing iPSCs with CRISPR/Cas9

Published on : Published by : Chris Frew

This rigorous three day program is ideal for basic research and translational biology scientists who are looking for a balanced theoretical vs. hands-on introduction to gene editing iPSCs using CRISPR/Cas9. [….]

5 Questions with Kurt Elam, Senior Director, Sales & Marketing for LabOwl

Published on : Published by : Andy Eckert

Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.

Experts Weigh in on the Role of Lab Automation and Sensor Technology in Advancing the Cell Therapy and Regenerative Medicine Fields

Published on : Published by : Steven Surdez

While there is tremendous excitement and ample investment around cell and gene therapy and regenerative medicine, several challenges, including scale-up, high manufacturing costs, and regulatory hurdles, continue to be impediments to the industry achieving its potential.

Regenerative Medicine Leaders Emphasized a Focus on Efficiencies and Collaboration to Make a Greater Impact on Patients

Published on : Published by : Chris Frew

Regenerative Medicine Leaders Emphasized a Focus on Efficiencies and Collaboration to Make a Greater Impact on Patients “We are here to bring the Community together to change the world!” opened [….]